Ansatipin (Rifabutin)
Antimycobacterial antibiotic for tuberculosis treatment and MAC infection prophylaxis
Quick Facts About Ansatipin (Rifabutin)
Key Takeaways About Ansatipin
- Dual indication: Ansatipin is used both for treating pulmonary tuberculosis and preventing MAC infections in immunocompromised patients
- Preferred in HIV patients: Rifabutin has fewer drug interactions with antiretroviral therapies compared to rifampicin, making it the preferred choice for HIV-positive TB patients
- Body fluid discoloration is normal: Urine, tears, sweat, and skin may turn reddish-orange during treatment; soft contact lenses may be permanently stained
- Watch for serious skin reactions: Stop the medication immediately and seek emergency care if you develop a rash with blisters, mouth sores, or widespread skin peeling
- Significant drug interactions: Must NOT be combined with ritonavir or long-acting rilpivirine injections; dose adjustments required with many other medications
What Is Ansatipin and What Is It Used For?
Ansatipin contains rifabutin, an antimycobacterial antibiotic that works by inhibiting bacterial RNA synthesis. It is prescribed for two main conditions: as part of a multi-drug regimen for pulmonary tuberculosis (TB), and as a prophylactic agent to prevent Mycobacterium avium complex (MAC) infections in patients with HIV/AIDS.
Rifabutin belongs to the ansamycin class of antibiotics, which are derived from the naturally occurring compound rifamycin S. These antibiotics work by binding to and inhibiting DNA-dependent RNA polymerase in susceptible bacteria, effectively blocking the transcription of genetic information into messenger RNA. This mechanism prevents the bacteria from producing essential proteins needed for survival and reproduction.
The drug demonstrates potent activity against a range of mycobacterial species, including Mycobacterium tuberculosis, the causative agent of tuberculosis, and Mycobacterium avium complex (MAC), which can cause serious disseminated infections in immunocompromised individuals. Unlike many antibiotics, rifabutin is effective against both actively multiplying and semi-dormant mycobacteria, making it particularly valuable in tuberculosis treatment where bacteria can exist in different metabolic states within the body.
Treatment of Pulmonary Tuberculosis
In the treatment of pulmonary tuberculosis, Ansatipin is used as part of a combination therapy, never as a single agent. Tuberculosis treatment requires multiple drugs to prevent the development of antibiotic resistance and to target bacteria in different phases of growth. The standard course of rifabutin-based TB treatment extends for up to 6 months, during which the patient takes the medication alongside other anti-tubercular agents such as isoniazid, pyrazinamide, and ethambutol. The WHO recommends rifabutin as an alternative to rifampicin, particularly when drug interactions pose a clinical concern.
Rifabutin offers a key pharmacological advantage over rifampicin: it is a less potent inducer of cytochrome P450 enzymes. This means it causes fewer and less severe drug interactions, which is critically important for patients who are also taking antiretroviral medications for HIV, antifungal agents, or immunosuppressive drugs. According to IDSA/ATS guidelines, rifabutin is the recommended rifamycin when patients cannot tolerate the drug interactions associated with rifampicin.
Prevention of MAC Infections in HIV/AIDS
Mycobacterium avium complex (MAC) is a group of bacteria found widely in the environment. In healthy individuals, MAC rarely causes disease. However, in people with severely weakened immune systems—particularly those with HIV/AIDS and a CD4 count below 50 cells/μL—MAC can cause disseminated infections affecting the blood, bone marrow, liver, spleen, and lymph nodes. These infections can be life-threatening if not prevented or treated.
Ansatipin at a dose of 300 mg once daily is recommended by the NIH and WHO for MAC prophylaxis in HIV patients with CD4 counts below 50 cells/μL who are not yet on effective antiretroviral therapy (ART). MAC prophylaxis can generally be discontinued once the patient achieves immune reconstitution with a sustained CD4 count above 100 cells/μL on effective ART for at least 3 months.
What Should You Know Before Taking Ansatipin?
Before starting Ansatipin, inform your doctor about all medical conditions, especially liver or kidney problems, jaundice, and all medications you are currently taking. Ansatipin must not be taken with ritonavir or long-acting rilpivirine injections, and it has significant interactions with many other drugs.
Contraindications
Ansatipin must not be taken in the following circumstances, as the risks clearly outweigh any potential benefits:
- Allergy to rifabutin or any excipient: Patients with a known hypersensitivity to rifabutin, other rifamycins (such as rifampicin or rifapentine), or any of the inactive ingredients in the capsule must not take this medication. Allergic reactions can range from mild skin rashes to severe anaphylaxis.
- Concurrent use of ritonavir: Ritonavir is a potent inhibitor of CYP3A4, the primary enzyme responsible for rifabutin metabolism. Co-administration dramatically increases rifabutin blood levels, significantly raising the risk of serious adverse effects including uveitis, neutropenia, and hepatotoxicity.
- Concurrent use of long-acting rilpivirine injections: Long-acting rilpivirine (given as an extended-release intramuscular injection) must not be used with rifabutin. Rifabutin induces the metabolism of rilpivirine, potentially reducing its plasma concentrations to subtherapeutic levels and increasing the risk of HIV treatment failure and viral resistance.
- Active jaundice: Patients with current jaundice (yellowing of the skin and eyes) should not begin rifabutin therapy. Jaundice indicates significant liver dysfunction, and since rifabutin is metabolized by the liver and can itself cause hepatotoxicity, starting the drug in this context could worsen liver damage.
Warnings and Precautions
Several clinical situations require special caution and careful monitoring during Ansatipin therapy. Discuss these with your prescribing physician before beginning treatment:
Liver impairment: Rifabutin undergoes extensive hepatic metabolism. Patients with pre-existing liver disease, including chronic hepatitis B or C, alcoholic liver disease, or drug-induced liver injury, require baseline liver function tests and regular monitoring throughout treatment. The risk of hepatotoxicity is increased when rifabutin is combined with isoniazid, another hepatotoxic anti-TB drug. According to the BNF, liver function should be monitored at regular intervals, and patients should be advised to report symptoms such as fatigue, abdominal pain, nausea, or dark urine immediately.
Kidney impairment: Patients with severely reduced kidney function (creatinine clearance below 30 mL/min) may require dose adjustments, as rifabutin metabolites are partially excreted by the kidneys. Your physician will determine the appropriate dose based on your kidney function tests.
Body fluid discoloration: Rifabutin and its metabolites cause a characteristic reddish-orange discoloration of body fluids. Urine, sputum, tears, saliva, sweat, and even the skin may turn reddish-brown or orange. This is a harmless pharmacological effect and not a sign of bleeding or disease. However, patients should be warned that soft contact lenses may become permanently stained. It is advisable to wear glasses or use daily disposable lenses during treatment.
Eye complications: Uveitis (inflammation of the middle layer of the eye) is a recognized adverse effect of rifabutin, particularly at higher doses or when combined with drugs that inhibit its metabolism, such as clarithromycin, fluconazole, or protease inhibitors. Patients should be instructed to report any eye pain, redness, light sensitivity, or changes in vision immediately. An ophthalmological examination should be arranged promptly if such symptoms occur.
Diarrhea: As with nearly all antibacterial agents, Ansatipin can cause diarrhea, including potentially severe Clostridioides difficile-associated diarrhea (CDAD). Patients should contact their physician if they develop significant diarrhea during or after treatment, even if it occurs weeks after the last dose.
Blood test interference: Rifabutin therapy can affect the results of certain laboratory tests, potentially leading to unreliable results. Inform all healthcare providers that you are taking rifabutin before any blood work is performed.
Pregnancy and Breastfeeding
Pregnancy: Clinical experience with rifabutin in pregnant women is limited. Animal studies have shown some evidence of embryotoxicity and teratogenicity at high doses. Rifabutin should only be used during pregnancy if the potential benefit to the mother clearly justifies the potential risk to the fetus. Women who are pregnant, planning to become pregnant, or suspect they may be pregnant should discuss the risks and benefits with their healthcare provider. The WHO emphasizes that tuberculosis itself poses significant risks during pregnancy, and treatment decisions must weigh both the disease and drug risks.
Breastfeeding: It is not known whether rifabutin is excreted in human breast milk. Given the potential for adverse effects in the nursing infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother. Consultation with a specialist is recommended.
Driving and Operating Machinery
Ansatipin has no known direct effect on the ability to drive or operate machinery. However, patients should be aware that some side effects, such as dizziness or visual disturbances (particularly uveitis), could impair their ability to perform these activities safely. Each patient is responsible for assessing their own fitness to drive. If you experience any symptoms that affect your alertness or vision, refrain from driving or operating machinery until the symptoms resolve.
Sodium Content
Ansatipin capsules contain less than 1 mmol sodium (23 mg) per capsule, meaning they are essentially sodium-free. This is relevant for patients on sodium-restricted diets.
How Does Ansatipin Interact with Other Drugs?
Ansatipin (rifabutin) is an inducer of cytochrome P450 3A4 (CYP3A4) enzymes and can significantly reduce the blood levels of many co-administered medications. Conversely, drugs that inhibit CYP3A4 can increase rifabutin levels and toxicity. Always inform your doctor about all medications you are taking.
Drug interactions are one of the most clinically important considerations when prescribing rifabutin. As a moderate inducer of CYP3A4 (less potent than rifampicin), rifabutin accelerates the metabolism of many drugs, lowering their blood concentrations and potentially reducing their effectiveness. At the same time, rifabutin is itself a substrate of CYP3A4, meaning drugs that inhibit this enzyme can increase rifabutin levels and enhance its toxicity.
The following table summarizes the most clinically significant drug interactions. This is not an exhaustive list—always consult your physician or pharmacist before starting or stopping any medication while taking Ansatipin.
Major Interactions
| Drug / Drug Class | Effect of Interaction | Clinical Recommendation |
|---|---|---|
| Ritonavir | Massively increased rifabutin levels (up to 4-fold); high risk of toxicity | Contraindicated. Do NOT use together. |
| Rilpivirine (long-acting injection) | Reduced rilpivirine levels; risk of HIV treatment failure | Contraindicated. Do NOT use together. |
| Clarithromycin | Increased rifabutin levels; significantly increased risk of uveitis | Dose reduction of rifabutin required. Close monitoring for eye symptoms. |
| Fluconazole | Increased rifabutin levels; increased risk of uveitis and neutropenia | Dose adjustment may be needed. Monitor blood counts and vision. |
| Itraconazole / Voriconazole / Posaconazole | Increased rifabutin levels; decreased azole antifungal levels | Monitor both drug levels. Dose adjustments may be required. |
| Tacrolimus | Reduced tacrolimus levels; risk of transplant rejection | Frequent tacrolimus level monitoring. Dose increase likely needed. |
| Bedaquiline | Reduced bedaquiline levels; reduced TB drug efficacy | Avoid combination if possible. Monitor closely if unavoidable. |
Other Notable Interactions
| Drug / Drug Class | Effect of Interaction | Clinical Recommendation |
|---|---|---|
| HIV protease inhibitors (other than ritonavir) | Increased rifabutin levels; decreased protease inhibitor levels | Rifabutin dose reduction to 150 mg daily or 300 mg 3x/week. Consult HIV specialist. |
| Sofosbuvir (hepatitis C) | Potentially reduced sofosbuvir efficacy | Monitor hepatitis C treatment response closely. |
| Oral contraceptives | Reduced contraceptive efficacy; risk of unintended pregnancy | Use additional or alternative contraception during treatment and for 1 month after. |
| Warfarin / Coumarins | Reduced anticoagulant effect | Frequent INR monitoring. Warfarin dose increase likely needed. |
| Corticosteroids | Reduced corticosteroid levels | May need corticosteroid dose increase. Monitor clinical response. |
What Is the Correct Dosage of Ansatipin?
The typical adult dose for pulmonary tuberculosis is 150–450 mg (1–3 capsules) daily for up to 6 months. For MAC prophylaxis in HIV/AIDS patients, the standard dose is 300 mg (2 capsules) once daily. Always follow your doctor's specific instructions.
Dosage of Ansatipin must be individualized based on the clinical indication, the patient's body weight, age, kidney function, and any concomitant medications that may interact with rifabutin. The following dosage guidelines are based on WHO, IDSA/ATS, and NIH recommendations. Always take this medication exactly as prescribed by your physician.
Adults
Pulmonary Tuberculosis
Dose: 150–450 mg (1–3 capsules) once daily
Duration: Up to 6 months as part of a multi-drug combination regimen
Note: Rifabutin replaces rifampicin in the standard regimen when drug interactions are a concern, particularly in HIV co-infected patients.
MAC Prophylaxis in HIV/AIDS
Dose: 300 mg (2 capsules) once daily
Duration: Continue until immune reconstitution is achieved on effective antiretroviral therapy (typically CD4 count above 100 cells/μL sustained for at least 3 months)
Note: Dose reduction to 150 mg daily may be required when co-administered with protease inhibitors.
Special Populations
| Patient Group | Recommended Dose | Notes |
|---|---|---|
| Adults (standard) | 150–450 mg/day (TB) or 300 mg/day (MAC) | Based on indication and concomitant medications |
| Elderly (>70 years) | Lower end of dose range | Increased risk of hepatotoxicity; monitor liver function |
| Body weight <50 kg | Reduced dose | Dose adjusted proportionally by physician |
| Severe renal impairment | Reduced dose | Creatinine clearance <30 mL/min requires dose adjustment |
| Co-administered with protease inhibitors | 150 mg daily or 300 mg 3x/week | Protease inhibitors increase rifabutin levels substantially |
Children
The use of Ansatipin in children has not been extensively studied. Pediatric dosing, when indicated, should be determined by a specialist physician experienced in treating childhood tuberculosis or opportunistic infections. The British National Formulary for Children (BNFC) and WHO guidelines provide specific weight-based dosing recommendations when rifabutin use in children is deemed necessary.
Missed Dose
If you forget to take a dose of Ansatipin, continue with your regular dosing schedule at the usual time. Do not take a double dose to make up for a missed one. If you are unsure about what to do, contact your physician or pharmacist for guidance. Consistency in taking anti-TB medications is critical for treatment success and preventing drug resistance, so try to take your medication at the same time each day.
Overdose
If you or someone else has taken more than the prescribed amount of Ansatipin, or if a child has accidentally ingested the medication, contact emergency services or your local poison control center immediately. Provide them with the name of the medication, the amount taken, and the time of ingestion. There is no specific antidote for rifabutin overdose; treatment is symptomatic and supportive. Activated charcoal may be considered if the overdose was recent and the patient is alert.
What Are the Side Effects of Ansatipin?
Like all medicines, Ansatipin can cause side effects, although not everyone experiences them. The most common side effect is a decrease in white blood cell count. Serious but rare side effects include severe skin reactions (SJS/TEN/DRESS), uveitis (eye inflammation), and agranulocytosis. Body fluid discoloration (reddish-orange) is expected and harmless.
The side effect profile of rifabutin has been well characterized through clinical trials and post-marketing surveillance. Most side effects are mild to moderate and resolve upon dose adjustment or discontinuation. However, some adverse effects are serious and require immediate medical attention. Below is a comprehensive overview organized by frequency.
- Severe skin rash with or without blisters, skin peeling, mouth/eye/genital sores (signs of SJS/TEN)
- Rash with swelling, fever, and flu-like symptoms developing 2–8 weeks after starting treatment (signs of DRESS)
- Fever with severely worsened general condition, sore throat, or difficulty urinating (signs of agranulocytosis)
- Eye pain, redness, sensitivity to light, or blurred vision (signs of uveitis)
Very Common
- Decreased white blood cell count (neutropenia/leukopenia)
Common
- Anemia (low red blood cell count)
- Skin rash
- Fever
- Nausea
- Altered taste (dysgeusia)
- Muscle pain (myalgia)
Uncommon
- Vomiting
- Changes in blood cell counts (thrombocytopenia, eosinophilia)
- Joint pain (arthralgia)
- Jaundice (yellowing of skin and eyes)
- Skin discoloration (brownish-orange)
Rare / Frequency Not Known
- Liver damage (hepatotoxicity, elevated transaminases)
- Uveitis (inflammation of the eye — especially with CYP3A4 inhibitors)
- Hypersensitivity reactions (including anaphylaxis in rare cases)
- Bronchospasm (airway constriction)
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- DRESS syndrome
- Acute generalized exanthematous pustulosis (AGEP)
- Agranulocytosis (severe drop in white blood cells)
- Clostridioides difficile-associated diarrhea
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorized is important. It allows continuous monitoring of the benefit/risk balance of the medicine. Healthcare professionals and patients are encouraged to report suspected adverse reactions through their national pharmacovigilance system. In the United States, reports can be submitted to the FDA MedWatch program. In the European Union, adverse reactions can be reported through national agencies such as the MHRA (UK), BfArM (Germany), or the EMA's EudraVigilance system.
How Should You Store Ansatipin?
Store Ansatipin capsules out of the sight and reach of children, at room temperature, in the original packaging. Do not use after the expiry date printed on the carton.
Proper storage of medications is essential to maintain their efficacy and safety. Ansatipin capsules should be stored under the following conditions:
- Keep out of the sight and reach of children: Store the medication in a secure location that children cannot access.
- Do not use after the expiry date: The expiry date is printed on the carton and blister pack. The date refers to the last day of the stated month. Expired medications may have reduced efficacy or altered safety profiles.
- Store at room temperature: Keep the capsules in a cool, dry place away from direct sunlight and moisture.
- Keep in original packaging: Protect the capsules from light and moisture by storing them in the original blister pack.
Do not dispose of medications by flushing them down the toilet or throwing them in household waste. Return unused or expired medications to a pharmacy for proper disposal. These measures help protect the environment from pharmaceutical contamination of water systems and soil.
What Does Ansatipin Contain?
Each Ansatipin capsule contains 150 mg of rifabutin as the active ingredient, along with inactive excipients including microcrystalline cellulose, gelatin, sodium lauryl sulfate, magnesium stearate, and colloidal anhydrous silica.
Active Ingredient
Each hard capsule contains 150 mg rifabutin. Rifabutin is a semi-synthetic ansamycin antibiotic derived from rifamycin S, with the molecular formula C46H62N4O11 and a molecular weight of approximately 847 g/mol. It appears as a crystalline brown powder.
Inactive Ingredients (Excipients)
- Microcrystalline cellulose (filler/binder)
- Gelatin (capsule shell)
- Sodium lauryl sulfate (wetting agent — see sodium content note below)
- Magnesium stearate (lubricant)
- Colloidal anhydrous silica (flow agent)
- Iron oxide E 172 (colorant)
- Titanium dioxide E 171 (colorant)
Appearance and Packaging
Ansatipin capsules are hard, reddish-brown capsules containing a brown, crystalline powder. They are supplied in blister packs of 30 capsules per box.
Frequently Asked Questions About Ansatipin
Rifabutin and rifampicin are both rifamycin antibiotics used to treat tuberculosis and mycobacterial infections. The key difference lies in their drug interaction profiles. Rifampicin is a very potent inducer of CYP3A4 and other cytochrome P450 enzymes, leading to substantial reductions in the blood levels of many co-administered drugs, including antiretrovirals, antifungals, and immunosuppressants. Rifabutin is a less potent enzyme inducer, causing fewer and less severe drug interactions. This makes rifabutin the preferred rifamycin for patients on complex medication regimens, particularly HIV-positive patients on antiretroviral therapy. Both drugs are equally effective against Mycobacterium tuberculosis.
It is strongly advisable to avoid alcohol while taking Ansatipin. Both rifabutin and alcohol are metabolized by the liver, and their combination increases the risk of hepatotoxicity (liver damage). Alcohol consumption can also exacerbate the gastrointestinal side effects of rifabutin, such as nausea and vomiting. If you are being treated for tuberculosis, which often involves multiple hepatotoxic drugs, alcohol abstinence is particularly important. Discuss any alcohol use with your physician.
Yes, this is completely normal and expected. Rifabutin and its metabolites produce a characteristic reddish-orange discoloration of urine, tears, sweat, saliva, and sputum. The skin may also take on a brownish-orange tint. This is a harmless pharmacological effect and does not indicate blood in the urine or any other medical problem. However, be aware that soft contact lenses can become permanently stained. Consider switching to glasses or daily disposable lenses during treatment.
Ansatipin can be taken with or without food. Food does not significantly affect the overall absorption of rifabutin. However, some patients find that taking the capsule with food helps reduce gastrointestinal side effects such as nausea. For optimal consistency, try to take the medication at the same time each day, either consistently with food or consistently on an empty stomach.
Rifabutin begins its antibacterial action within hours of the first dose, but clinical improvement in tuberculosis or MAC infection develops gradually over weeks. For TB treatment, sputum cultures typically become negative within 2–3 months of appropriate multi-drug therapy. For MAC prophylaxis, the drug works preventively, and its effectiveness is measured by the absence of MAC infection development rather than symptom resolution. It is essential to complete the full course of treatment even if you feel well, as premature discontinuation can lead to treatment failure and drug resistance.
Both Ansatipin and Mycobutin contain the same active ingredient, rifabutin, at the same strength (150 mg capsules). They are different brand names for the same medication, manufactured by different pharmaceutical companies in different countries. Ansatipin is marketed by Pfizer in certain European markets. The therapeutic effects, side effects, and dosing recommendations are identical for both products.
References
- World Health Organization (WHO). WHO consolidated guidelines on tuberculosis: Module 4 – Treatment: drug-susceptible tuberculosis treatment. Geneva: WHO; 2022. Available at: who.int
- Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. doi: 10.1093/cid/ciw376
- Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health (NIH); 2024. Available at: clinicalinfo.hiv.gov
- European Medicines Agency (EMA). Summary of Product Characteristics: Rifabutin. EMA; 2024.
- British National Formulary (BNF). Rifabutin. NICE Evidence Services; 2024. Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Mycobutin (rifabutin) Prescribing Information. FDA; 2023.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49(9):1305–1311.
- Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: reprise. Clin Infect Dis. 2008;47(5):712–720.
- Griffith DE, Aksamit T, Brown-Elliott BA, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians specialized in infectious disease, clinical pharmacology, and internal medicine. All content follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, IDSA/ATS, and BNF.
iMedic Medical Editorial Team — specialists in infectious disease and pharmacology with documented clinical and academic experience.
iMedic Medical Review Board — independent panel of medical experts reviewing all content according to international treatment guidelines and evidence-based medicine standards.
Evidence Level: This article is based on Level 1A evidence, the highest quality of evidence derived from systematic reviews of randomized controlled trials, international clinical guidelines, and approved product information from regulatory agencies.
Conflict of Interest: The iMedic Medical Editorial Team has no financial relationships with pharmaceutical companies. All content is independently produced with no commercial funding or sponsorship.